Fact CheckerSign in

NCT06655389Recruiting

Correlation Between PLA Levels and Disease Severity in Patients With Sepsis Cardiac Insufficiency

Source: ClinicalTrials.gov · Last updated 23 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Sepsis cardiac insufficiency is characterized by high morbidity and mortality. Studies have shown an association between elevated PLA levels in patients with sepsis and clinical outcomes of cardiac dysfunction. This study will explore the correlation between circulating PLA levels and organ dysfunction and disease severity in SIMD patients in the form of a cross-sectional study.

Status (registry)
Recruiting
Study type
Observational
Enrollment
30 (estimated)
First submitted
22 Oct 2024
Start date
1 May 2024
Primary completion date
31 Dec 2026
Lead sponsor
Dongzhimen Hospital, Beijing
NCT number
NCT06655389

What you commit to

  • Study type: Observational
  • Planned participants: 30
  • From 1 May 2024 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • 1\) Diagnosed with acute coronary syndrome, old myocardial infarction, and coronary heart disease revascularization of patients; (2) Cardiac insufficiency due to cardiomyopathy, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, myocardial amyloidosis, diabetic cardiomyopathy, hypothyroidic cardiomyopathy, etc.; (3) Due to heart knots Cardiac insufficiency caused by structural abnormalities, arrhythmias, cor pulmonale, nephroheart syndrome, etc.; (4) Impact Survival of severe primary diseases, including: uncontrolled malignant tumors that have metastasized in multiple places and cannot be resected, and blood disease, novel coronavirus infection and HIV, etc.; (5) Liver and kidney dysfunction with a single SOFA score of ≥3 points in liver or kidney handicappers; (6) Those who have been continuously using immunosuppressants or organ transplantation in the past 6 months; (7) 7 consecutive days prior to enrollment Those who have used corticosteroids, converted to methylprednisolone dose≥ 20mg/day; (8) Pregnant and lactating women; (9) Take or Injection of drugs that affect platelet function and coagulation function; (10) Those who have participated in other clinical trials within 30 days.

Who the study is looking for

  • Sepsis cardiac insufficiency group
    • From April 2024 to December 2026, in the first ICU area of Dongzhimen Hospital, Beijing University of Chinese Medicine, Hospitalized patients in Zone II;
    • consistent with the diagnosis of sepsis cardiac insufficiency;
    • Age ≥ 50 and ≤ 90 years old;
    • SOFA score≥ 2 points;
    • Within 24 hours of the diagnosis of cardiac insufficiency in sepsis;
    • The patient or his/her family members sign the informed consent form. Healthy subjects
    • <!-- -->
    • Aged ≥ 50 and ≤ 90 years old, permanent residents of Beijing community;
    • Good health (blood routine, liver and kidney function, blood lipids, blood coagulation, no obvious abnormalities, no diagnosis cardiac insufficiency, acute coronary syndrome, old myocardial infarction, or cardiomyopathy);
    • There is no history of long-term use of drugs that affect platelet function and coagulation function, and those who are willing to cooperate with the test Crowd;
    • The subject himself signed the informed consent form.

Age in the registry: 50 years to 90 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
DongzhimenH,Beijing
Coordinator of this site? Confirm its status
BeijingChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.